CoverMyMeds plans leadership changes with CEO set to depart
CoverMyMeds co-founder and CEO Matt Scantland announced Friday that he will be relinquishing his role by the end of the year. David Holladay has been named president and Scott Gaines will assume the role of COO.
Holladay has been senior vice president and GM of the payer business at CoverMyMeds. Previously, he was a senior executive at Cigna, Humana, and technology company RxEDO. Gaines has been a key part of building CoverMyMeds during the five years he has been with the company. He was senior vice president and GM of provider solutions at CoverMyMeds, and prior to that was a leader in the global healthcare business of Cleveland-based technology firm, Hyland.
In an open letter on CoverMyMeds website where he announced his impending departure, Scantland said that what started as an idea by a small and committed team has now grown to a company of more than 1,000 leaders working together to solve some of healthcare’s biggest problems.
“We’ve done this by empowering our employees to build a great company because they understand our mission of helping patients get the medications they need to live healthy lives, and know that we can accomplish anything if we solve important problems in a way where everyone in our industry wins,” he wrote. “Today, by nearly any measure, CoverMyMeds is three times larger than in 2017 when we joined McKesson as the largest technology deal ever in Ohio, and one of the largest digital health acquisitions in the country.”
He noted that longtime COO Michelle Brown would focus on leadership initiatives across McKesson. “Michelle has played an irreplaceable part in building our company from the very beginning, and we are excited about what she will do next,” he wrote.
Scantland said that he McKesson CEO Brian Tyler share mutual gratitude “about what we accomplished, and how bright the future is between CoverMyMeds and McKesson.”
“CoverMyMeds’ impact goes right to the heart of the McKesson growth strategies in specialty, manufacturer value proposition and future retail models. We have an opportunity to contribute to the future as part of one of the few companies in the world that can reinvent healthcare for the good of millions of patients who are counting on us. I have a great deal of respect for Matt’s unique leadership and view of the world, and will miss working with him,” he wrote. “We are grateful for the contributions he has made, and it is an honor to both Matt and me that we are making this transition after so much success between us, and with an incredible growth path and leadership team in place. I wish Matt all the best and hope our paths will cross again.”
No comments found